An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Dapagliflozin 70 mg Extended Release Capsules in Healthy Volunteers
Latest Information Update: 12 Apr 2021
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 09 Apr 2021 Status changed from recruiting to completed.
- 12 Nov 2020 New trial record